95 related articles for article (PubMed ID: 16612034)
1. Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals.
Ferre PJ; Laroute V; Braun JP; Cazaux J; Toutain PL; Lefebvre HP
J Anim Sci; 2006 May; 84(5):1295-301. PubMed ID: 16612034
[TBL] [Abstract][Full Text] [Related]
2. A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses.
Toutain PL; Lassourd V; Costes G; Alvinerie M; Bret L; Lefebvre HP; Braun JP
J Vet Pharmacol Ther; 1995 Jun; 18(3):226-35. PubMed ID: 7674460
[TBL] [Abstract][Full Text] [Related]
3. The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses.
Mills PC; Ng JC; Auer DE
J Vet Pharmacol Ther; 1996 Dec; 19(6):475-81. PubMed ID: 8971677
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of phenylbutazone in calves.
Arifah AK; Lees P
J Vet Pharmacol Ther; 2002 Aug; 25(4):299-309. PubMed ID: 12213119
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep.
Cheng Z; McKeller Q; Nolan A
J Vet Pharmacol Ther; 1998 Aug; 21(4):315-21. PubMed ID: 9731955
[TBL] [Abstract][Full Text] [Related]
6. [Bioavailability of muscle creatine kinase in sheep. Application to the assessment of local tolerance to injectable veterinary formulations].
Verlinde V; Mikaelian I; Laurentie M; Sanders P; Poul JM
Vet Res; 1996; 27(2):133-46. PubMed ID: 8721293
[TBL] [Abstract][Full Text] [Related]
7. Disposition and tolerance of suxibuzone in horses.
Jaraiz MV; Rodriguez C; San Andres MD; Gonzalez F; San Andres MI
Equine Vet J; 1999 Sep; 31(5):411-6. PubMed ID: 10505957
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses.
Jaraiz V; Rodriguez C; San Andres MD; Gonzalez F; San Andres MI
J Vet Pharmacol Ther; 1999 Aug; 22(4):247-54. PubMed ID: 10499236
[TBL] [Abstract][Full Text] [Related]
9. In vivo non-invasive quantification of muscle damage following a single intramuscular injection of phenylbutazone in sheep.
Houpert P; Serthelon JP; Lefebvre HP; Toutain PL; Braun JP
Vet Hum Toxicol; 1995 Apr; 37(2):105-10. PubMed ID: 7631487
[TBL] [Abstract][Full Text] [Related]
10. Phenylbutazone in racing greyhounds: plasma and urinary residues 24 and 48 hours after a single intravenous administration.
Mills PC; Ng JC; Skelton KV; Seawright AA; Auer DE
Aust Vet J; 1995 Aug; 72(8):304-8. PubMed ID: 8579562
[TBL] [Abstract][Full Text] [Related]
11. Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius).
Kadir A; Ali BH; al Hadrami G; Bashir AK; Landoni MF; Lees P
J Vet Pharmacol Ther; 1997 Feb; 20(1):54-60. PubMed ID: 9049950
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release.
Lefebvre HP; Laroute V; Braun JP; Lassourd V; Toutain PL
Vet Res; 1996; 27(4-5):343-61. PubMed ID: 8822606
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of methocarbamol and phenylbutazone in exercised Thoroughbred horses.
Knych HK; Stanley SD; Seminoff KN; McKemie DS; Kass PH
J Vet Pharmacol Ther; 2016 Oct; 39(5):469-77. PubMed ID: 26924025
[TBL] [Abstract][Full Text] [Related]
14. Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses.
Knych HK; Arthur RM; McKemie DS; Seminoff K; Hamamoto-Hardman B; Kass PH
Drug Test Anal; 2019 Jun; 11(6):792-803. PubMed ID: 30499176
[TBL] [Abstract][Full Text] [Related]
15. Disposition of creatine kinase activity in dog plasma following intravenous and intramuscular injection of skeletal muscle homogenates.
Aktas M; Lefebvre HP; Toutain PL; Braun JP
J Vet Pharmacol Ther; 1995 Feb; 18(1):1-6. PubMed ID: 7752299
[TBL] [Abstract][Full Text] [Related]
16. Effects of phenylbutazone alone or in combination with flunixin meglumine on blood protein concentrations in horses.
Reed SK; Messer NT; Tessman RK; Keegan KG
Am J Vet Res; 2006 Mar; 67(3):398-402. PubMed ID: 16506899
[TBL] [Abstract][Full Text] [Related]
17. The disposition of suxibuzone in the horse.
Delbeke FT; Vynckier L; Debackere M
J Vet Pharmacol Ther; 1993 Sep; 16(3):283-90. PubMed ID: 8230399
[TBL] [Abstract][Full Text] [Related]
18. [The concentration changes of different phenylbutazone formulations in horse plasma].
Keller H; Hashem A
Dtsch Tierarztl Wochenschr; 1996 Jun; 103(6):224-30. PubMed ID: 8766906
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls.
Williams RJ; Smith JA; Boudinot FD; Knight AP
Am J Vet Res; 1990 Mar; 51(3):367-70. PubMed ID: 2316911
[TBL] [Abstract][Full Text] [Related]
20. The intramuscular bioavailability of a phenylbutazone preparation in the horse.
Landuyt J; Delbeke FT; Debackere M
J Vet Pharmacol Ther; 1993 Dec; 16(4):494-500. PubMed ID: 8126767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
